Latest research on Rosuvastatin

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Rosuvastatin interactions

The available studies have also shown that the effectiveness of statin therapy, especially high-intensive regimens with Rosuvastatin 20–40 mg and Atorvastatin 40–80 mg, could be very high, and even in >90 % of patients we might achieve lipid goals [14]. [source, 2016]
Several factors can influence residual risk; this is associated with patients at very high risk with concomitant diseases and polypharmacy, and the problem of significant underuse of high doses of statins – in many European countries as well as in the United States Atorvastatin 80 mg or Rosuvastatin 40 mg is used in <5 % of dyslipidaemic patients [20–22]. [source, 2016]
A growing number of statins such as LOVASTATIN, Atorvastatin, Simvastatin, Pravastatin, Fluvastatin, pitavastatin, Rosuvastatin, and others (Supplementary Figure 3) and combinations thereof are on the market. [source, 2016]
Likewise, in the TAA model in rats both Atorvastatin and Rosuvastatin failed to inhibit liver cirrhosis or oxidative stress formation and had no effect of HSC proliferation (Shirin et al., 2013). [source, 2016]
At discharge, all patients received statins; 24 were on 20mg of Atorvastatin and 3 were on 10mg of Rosuvastatin. [source, 2016]
A recent study investigating the short-term (13 days) effect of statins on the urinary protein concentration and proteome in healthy volunteers found that either Rosuvastatin (40 mg/day) or Pravastatin (80 mg/day) did not induce major changes in the urinary protein concentration/proteome (on a background of high variability in the baseline urinary proteome/proteins among volunteers 191). [source, 2015]
Up-to-date studies on sympathetic activity with hydrophilic statins such as Pravastatin or Rosuvastatin are limited and so far the studies in humans with the use of microneurography are lacking. [source, 2015]
Daily treatment of the patient was composed of Gliclazide 60 mg, esomeprazole 20 mg, Atenolol 100 mg, altizide 15 mg + spironolactone 25 mg, attapulgite 3 g, bromide otilonium 120 mg, acetylsalycilic acid 80 mg, Rosuvastatin 20 mg, bromazepam 6 mg, and Lisinopril 20 mg (she has been taking it since 2007). [source, 2015]
This study evaluated these hypotheses by investigating the in vivo time-dependent and dose-dependent effects of daily Atorvastatin or Rosuvastatin oral therapy initiated either 1 day or 3 days after venous thrombosis (VT) formation, in established, already formed stasis or nonstasis chemical-induced murine VT. [source, 2015]
In addition, evaluation of combination daily statin (Atorvastatin 1.14mg/kg or Rosuvastatin 0.84 mg/kg) and enoxaparin 10 mg/kg LMWH therapy was examined. [source, 2015]